Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors

Drug Metabolism and Disposition

Volumn 39, Issue 2, 2011, Pages 322-329

  Zhou, Jin ^a   Tracy, Timothy S ^b   Remmel, Rory P ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 NAPHTHOL; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTHRAFLAVIC ACID; BILIRUBIN; CARVEDILOL; DAIDZEIN; ENZYME INHIBITOR; ESTRADIOL DERIVATIVE; ETHINYLESTRADIOL; GLUCURONOSYLTRANSFERASE 1A1; KETOCONAZOLE; LEVOTHYROXINE; NIFLUMIC ACID; RILUZOLE; RITONAVIR; URIDINE DIPHOSPHATE;

ARTICLE; CONCENTRATION RESPONSE; CORRELATION ANALYSIS; GLUCURONIDATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; KIDNEY; KINETICS; METABOLISM; METABOLITE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BILIRUBIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ESTRADIOL; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HEK293 CELLS; HUMANS; PHARMACEUTICAL PREPARATIONS; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY;

EID: 79251474385     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.035030     Document Type: Article

References (37)

1. Beutler E, Gelbart T, and Demina A (1998) Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA 95:8170-8174.
2. Brierley CH and Burchell B (1993) Human UDP-glucuronosyl transferases: chemical defence, jaundice and gene therapy. Bioessays 15:749-754.
3. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
4. Ciotti M and Owens IS (1996) Evidence for overlapping active sites for 17 α-ethynylestradiol and bilirubin in the human major bilirubin UDP-glucuronosyltransferase. Biochemistry 35: 10119-10124.
5. Court MH (2005) Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases. Methods Enzymol 400:104-116.
6. 139Lys isoform. Drug Metab Dispos 34:943-949.
7. Fisher MB, Paine MF, Strelevitz TJ, and Wrighton SA (2001) The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metab Rev 33:273-297.
8. Gupta B, LeVea C, Litwin A, and Fakih MG (2007) Reversible grade 4 hyperbilirubinemia in a patient with UGT1A1 7/7 genotype treated with irinotecan and cetuximab. Clin Colorectal Cancer 6:447-449.
9. Hanioka N, Ozawa S, Jinno H, Ando M, Saito Y, and Sawada J (2001) Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin. Xenobiotica 31:687-699.
10. Houston JB and Galetin A (2005) Modelling atypical CYP3A4 kinetics: principles and pragmatism. Arch Biochem Biophys 433:351-360.
11. Huber W and Koella JC (1993) A comparison of three methods of estimating EC50 in studies of drug resistance of malaria parasites. Acta Trop 55:257-261.
12. Hutzler JM, Hauer MJ, and Tracy TS (2001) Dapsone activation of CYP2C9-mediated metabolism: evidence for activation of multiple substrates and a two-site model. Drug Metab Dispos 29:1029-1034.
13. Kadakol A, Ghosh SS, Sappal BS, Sharma G, Chowdhury JR, and Chowdhury NR (2000) Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype. Hum Mutat 16:297-306.
14. Kenworthy KE, Clarke SE, Andrews J, and Houston JB (2001) Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism. Drug Metab Dispos 29:1644-1651.
15. Korzekwa KR, Krishnamachary N, Shou M, Ogai A, Parise RA, Rettie AE, Gonzalez FJ, and Tracy TS (1998) Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 37:4137-4147.
16. Lépine J, Bernard O, Plante M, Têtu B, Pelletier G, Labrie F, Bélanger A, and Guillemette C (2004) Specificity and regioselectivity of the conjugation of estradiol, estrone, and their catecholestrogen and methoxyestrogen metabolites by human uridine diphosphoglucuronosyltransferases expressed in endometrium. J Clin Endocrinol Metab 89:5222-5232.
17. Mano Y, Usui T, and Kamimura H (2007) Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol 101:211-214.
18. Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, and Sparreboom A (2001) Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 7:2182-2194.
19. Miners JO, Mackenzie PI, and Knights KM (2010) The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential. Drug Metab Rev 42:189-201.
20. Nielsen IL and Williamson G (2007) Review of the factors affecting bioavailability of soy isoflavones in humans. Nutr Cancer 57:1-10.
21. Pfeiffer E, Treiling CR, Hoehle SI, and Metzler M (2005) Isoflavones modulate the glucuronidation of estradiol in human liver microsomes. Carcinogenesis 26:2172-2178.
22. Radominska-Pandya A, Czernik PJ, Little JM, Battaglia E, and Mackenzie PI (1999) Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab Rev 31:817-899.
23. Ren Q, Murphy SE, Zheng Z, and Lazarus P (2000) O-Glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) by human UDP-glucuronosyltransferases 2B7 and 1A9. Drug Metab Dispos 28:1352-1360.
24. Rios GR and Tephly TR (2002) Inhibition and active sites of UDP-glucuronosyltransferases 2B7 and 1A1. Drug Metab Dispos 30:1364-1367.
25. Rotger M, Taffe P, Bleiber G, Gunthard HF, Furrer H, Vernazza P, Drechsler H, Bernasconi E, Rickenbach M, Telenti A, et al. (2005) Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J Infect Dis 192:1381-1386.
26. Segel IH (1975) Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems. John Wiley & Sons, Inc., New York.
27. Shou M, Lin Y, Lu P, Tang C, Mei Q, Cui D, Tang W, Ngui JS, Lin CC, Singh R, et al. (2001) Enzyme kinetics of cytochrome P450-mediated reactions. Curr Drug Metab 2:17-36.
28. Soars MG, Ring BJ, and Wrighton SA (2003) The effect of incubation conditions on the enzyme kinetics of UDP-glucuronosyltransferases. Drug Metab Dispos 31:762-767.
29. Stone AN, Mackenzie PI, Galetin A, Houston JB, and Miners JO (2003) Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human UDP-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7. Drug Metab Dispos 31:1086-1089.
30. Strassburg CP (2008) Pharmacogenetics of Gilbert's syndrome. Pharmacogenomics 9:703-715.
31. Tracy TS and Hummel MA (2004) Modeling kinetic data from in vitro drug metabolism enzyme experiments. Drug Metab Rev 36:231-242.
32. Uchaipichat V, Galetin A, Houston JB, Mackenzie PI, Williams JA, and Miners JO (2008) Kinetic modeling of the interactions between 4-methylumbelliferone, 1-naphthol, and zidovudine glucuronidation by UDP-glucuronosyltransferase 2B7 (UGT2B7) provides evidence for multiple substrate binding and effector sites. Mol Pharmacol 74:1152-1162.
33. Udomuksorn W, Elliot DJ, Lewis BC, Mackenzie PI, Yoovathaworn K, and Miners JO (2007) Influence of mutations associated with Gilbert and Crigler-Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A substrates. Pharmacogenet Genomics 17:1017-1029.
34. Williams JA, Ring BJ, Cantrell VE, Campanale K, Jones DR, Hall SD, and Wrighton SA (2002) Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol- 3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes. Drug Metab Dispos 30:1266-1273.
35. Zhang D, Zhang D, Cui D, Gambardella J, Ma L, Barros A, Wang L, Fu Y, Rahematpura S, Nielsen J, et al. (2007) Characterization of the UDP glucuronosyltransferase activity of human liver microsomes genotyped for the UGT1A1*28 polymorphism. Drug Metab Dispos 35: 2270-2280.
36. Zhou J, Tracy TS, and Remmel RP (2010a) Bilirubin glucuronidation revisited: proper assay conditions to estimate enzyme kinetics with recombinant UGT1A1. Drug Metab Dispos 38:1907-1911.
37. Zhou J, Tracy TS, and Remmel RP (2010b) Glucuronidation of dihydrotestosterone and trans-androsterone by recombinant UDP- glucuronosyltransferase (UGT) 1A4: evidence for multiple UGT1A4 aglycone binding sites. Drug Metab Dispos 38:431-440.